Abstract: A device for evaluating the service life of a bearing includes an operating condition obtainment unit configured to obtain a current operating condition of the bearing, a first acquisition unit configured to acquire a current vibration signal of the bearing under the current operating condition, a computation unit configured to compute a current vibration value of the bearing, a spalling obtainment unit configured to obtain a current surface spalling area of the bearing corresponding to the current vibration value of the bearing and further configured to obtain a current spalling rate of the bearing under the current operating condition, and a replacement reminder unit configured to transmit a bearing replacement reminder information when the current surface spalling area of the bearing is detected to be greater than a predetermined first area.

Abstract: A device for evaluating the service life of a bearing includes an operating condition obtainment unit configured to obtain a current operating condition of the bearing, a first acquisition unit configured to acquire a current vibration signal of the bearing under the current operating condition, a computation unit configured to compute a current vibration value of the bearing, a spalling obtainment unit configured to obtain a current surface spalling area of the bearing corresponding to the current vibration value of the bearing and further configured to obtain a current spalling rate of the bearing under the current operating condition, and a replacement reminder unit configured to transmit a bearing replacement reminder information when the current surface spalling area of the bearing is detected to be greater than a predetermined first area.

Abstract: Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.

Abstract: The invention includes compounds useful for inhibiting RSV replication and treating a host infected with RSV. The invention also includes methods of treating a host infected with RSV by administering to the host an anti-RSV effective amount of a compound of the invention.

Abstract: Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.